| Followers | 232 |
| Posts | 26887 |
| Boards Moderated | 0 |
| Alias Born | 01/12/2013 |
Sunday, February 19, 2017 8:53:42 AM
G- "only BB was entitled to submit more than one guess due to ... "
Biobillionair: stop / Jun. 30. / Sep. 29. / 41.00% **
Above 80% event June 30 was based on model, model updated with P/Y update. I rebuilt the x-axis, it matches Amarin guidance and December 31, 2017 P/Y 32,900.
Final composite ~ 4.9% 80% (event) should have occurred mid February...but efficacy should push 80% event out. Not out to June; note the change is due to updated x-axis, which has always been planned with any updated information from Amarin.
If I had to guess the placebo rate it would be >6%. 75% of R-I is likely to be type 2 DM.
Composite ~ 4.9%
Placebo >6% (From my professional experience it's reasonable to assume 6/100 metabolic disease patients, diabetics with high trigs, would have an event over the coarse of 1 year. My job is to manipulate physiology so these patients don't have acute events when they have surgery. The population of patients I serve are very very high risk, on occasion they are actively having 'an event'.)
Active arm ~ 3.9%
3.9/6 = RRR = 35% give me +/- 5% error and the range is ~ 30%-40%. If 80% event is pushed out to March-April then I guess we'll be in the upper range.
1612 will occur in 2017 as guided by Amarin.
My model will update with any new information of P/Y or 80% news.
This fight is personal to me.
BB
Biobillionair: stop / Jun. 30. / Sep. 29. / 41.00% **
Above 80% event June 30 was based on model, model updated with P/Y update. I rebuilt the x-axis, it matches Amarin guidance and December 31, 2017 P/Y 32,900.
Final composite ~ 4.9% 80% (event) should have occurred mid February...but efficacy should push 80% event out. Not out to June; note the change is due to updated x-axis, which has always been planned with any updated information from Amarin.
If I had to guess the placebo rate it would be >6%. 75% of R-I is likely to be type 2 DM.
Composite ~ 4.9%
Placebo >6% (From my professional experience it's reasonable to assume 6/100 metabolic disease patients, diabetics with high trigs, would have an event over the coarse of 1 year. My job is to manipulate physiology so these patients don't have acute events when they have surgery. The population of patients I serve are very very high risk, on occasion they are actively having 'an event'.)
Active arm ~ 3.9%
3.9/6 = RRR = 35% give me +/- 5% error and the range is ~ 30%-40%. If 80% event is pushed out to March-April then I guess we'll be in the upper range.
1612 will occur in 2017 as guided by Amarin.
My model will update with any new information of P/Y or 80% news.
This fight is personal to me.
BB
Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
